Floatz logo

Cediranib

Malignant Peritoneal Neoplasm

Mayo ClinicSmall moleculePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Peritoneal Neoplasm cohort.

Asset / SponsorPhaseRating
Ipilimumab
Inge Marie Svane
Phase 1/2B
5-azacytidine
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →